Related Experiment Video

Updated: Jan 6, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.2K

Non-coding RNAs' pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review

Seyed Mostafa Rahimi1, Abouzar Bagheri2,3

  • 1Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.

Medical Oncology (Northwood, London, England)
|September 13, 2025
PubMed

Insights

MicroRNAs (miRNAs) and non-coding RNAs influence cancer treatment outcomes. Understanding their interaction with Topotecan chemotherapy can improve cancer therapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer remains a leading global cause of death, necessitating improved treatment strategies.
  • Topotecan is a chemotherapy agent used against various cancers, but its efficacy is limited by drug resistance.
  • MicroRNAs (miRNAs) and other non-coding RNAs are key regulators of chemotherapy resistance.

Purpose of the Study:

  • To systematically review the interaction mechanisms between non-coding RNAs and Topotecan.
  • To investigate how these interactions modulate cancer sensitivity to Topotecan chemotherapy.

Main Methods:

  • Systematic literature review adhering to PRISMA guidelines.
  • Comprehensive searches of PubMed, Scopus, and Web of Science databases.
  • Inclusion of eleven studies based on predefined selection criteria.

Main Results:

  • Altered non-coding RNA expression, particularly miRNAs, significantly impacts cancer sensitivity to Topotecan.
  • These regulatory effects occur through direct and indirect modulation of signaling pathways.
  • Impacts were observed across diverse cancer types, including retinoblastoma, colorectal, breast, and prostate cancers.

Conclusions:

  • Non-coding RNAs, especially miRNAs, are critical in determining cancer cell and model response to Topotecan.
  • Targeting these RNA molecules presents potential novel strategies for enhancing Topotecan chemotherapy efficacy.
  • Further research into these interactions could lead to improved therapeutic interventions for various cancers.
Keywords:
CancerChemosensitivityNon-coding RNAsTopotecanmiRNAs

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K